Impact of the ISCHEMIA Trial on Stress Nuclear Myocardial Perfusion Imaging

Venkatesh L. Murthy, MD, PhD (1); Timothy M. Bateman, MD (2); Wengen Chen, MD, PhD (3); Saurabh Malhotra, MD, MPH (4,5); Edward J. Miller, MD (6); Terrence D. Ruddy, MD (7); and Vasken Dilsizian, MD (3) on behalf of the Society of Nuclear Medicine and Molecular Imaging Cardiovascular Council

(1) Division of Cardiovascular Medicine and Frankel Cardiovascular Center, University of Michigan, Ann Arbor
(2) Mid America Heart Institute and the Saint-Luke’s Health System, University of Missouri-Kansas City, Kansas City, MO
(3) Department of Diagnostic Radiology and Nuclear Medicine, University of Maryland School of Medicine, Baltimore, MD
(4) Division of Cardiology, Cook County Health, Chicago, IL
(5) Division of Cardiology, Rush Medical College, Chicago, IL
(6) Section of Cardiovascular Medicine, Yale School of Medicine, New Haven, CT
(7) University of Ottawa Heart Institute, Ottawa, ON

Correspondence:
Venkatesh L. Murthy, MD, PhD
Associate Professor of Cardiovascular Medicine
University of Michigan
1338 Cardiovascular Center
1500 E. Medical Center Dr, SPC 5873
Ann Arbor, MI 48109
Phone: (734) 936-5387
Fax: (734) 232-3246
Email: vlmurthy@med.umich.edu

Word count: 2242
Introduction

The International Study of Comparative Health Effectiveness with Medical and Invasive Approaches (ISCHEMIA) was a randomized trial of 5,179 patients comparing the effects of optimal medical therapy versus the combination of optimal medical therapy and coronary revascularization on major adverse cardiac outcomes in patients with moderate to severe ischemia.(1, 2) Overall the ISCHEMIA trial found that revascularization did not lower the rates of major adverse cardiac outcomes nor cardiac death. However, unblinded revascularization did improve angina symptoms and quality of life for patients with daily to monthly angina at baseline.(3) There has been broad discussion and many strong proclamations of the implications of these data on the practice of clinical cardiology. Given the substantial implications on management of patients with known or suspected coronary artery disease (CAD), the Cardiovascular Council of the Society of Nuclear Medicine and Molecular Imaging, the leading professional society related to the practice of nuclear medicine imaging, would like to offer its preliminary perspective on these data.

Preliminary Data and Motivation for the Trial

The initial impetus for this trial was observational data from a single US center demonstrating that patients with ischemia affecting >10-12.5% of the left ventricular myocardium on stress single photon emission computed tomography (SPECT) myocardial perfusion imaging who underwent early revascularization had lower mortality than those who did not.(4, 5) A critical issue with observational data is the potential for biased referral for revascularization leading to a correlation between revascularization and outcomes without causation. The authors used propensity methods to reduce the likelihood of this type of erroneous conclusion, although only randomization can eliminate it entirely. Consequently, use of a simple heuristic that >10% ischemia should drive early revascularization in suitable patients became widespread. Since the time of these studies, there have been substantial improvements in the nature and utilization of optimal medical therapy as well as in revascularization devices and techniques to reduce the rate of serious complications. Further, until recently, no similar data were published from any other groups nor with any other stress testing modalities. Given the costs and potential complications associated with coronary revascularization, the National Heart, Lung, and Blood Institute funded the ISCHEMIA trial to assess this practice more rigorously.

Study Design and Implementation

Performing a large and complex randomized trial such as ISCHEMIA is a massive undertaking and the trialists and investigators deserve congratulations for completing this effort. Nonetheless, a large and complex trial, such as this, necessitates compromises in design which can have implications on interpretation. The limitations of design in the ISCHEMIA trial have been discussed in depth.(6) The most serious of these is that preliminary data from the earlier studies suggested that as a group, outcomes among patients with >10-12.5% ischemia on SPECT myocardial perfusion imaging were better with early revascularization. However, at exactly 10-12.5% ischemia, outcomes were identical. Indeed, the observed survival did not actually diverge until >15% ischemia was observed. In order to facilitate recruitment, the initial study design permitted stress testing with nuclear, echocardiographic, or magnetic resonance imaging, with compromises made due to limited evaluation of some portions of the heart with non-nuclear testing.(7) The initial plan was to mandate core lab confirmation of sufficient ischemia prior to randomization, although this requirement was lifted in the interest of improving trial flow. Furthermore, even the requirement for stress imaging was eventually lifted and patients with...
stress EKG without imaging were permitted to be enrolled. There has been no preliminary data showing that this modality is able to identify patients for whom revascularization may be beneficial. Given limited sensitivity and specificity, marked differences in referral patterns and potential for confounding by frailty, this was a major compromise. In the end, only 33.8% of the population randomized (N=1,748) had imaging evidence of severe myocardial ischemia. Of these, only 970 (18.7% of those randomized) had severe ischemia on nuclear imaging, for which there was pre-trial data supporting benefit from revascularization.

How serious a compromise was this? First, patients who underwent stress EKG without imaging comprised a larger share of the trial population (24.5%) than those for whom preliminary data which motivated this trial suggested might benefit from revascularization (namely those with moderate or greater ischemia on a stress nuclear myocardial perfusion imaging study). Further compounding this limitation, all the non-imaging patients were characterized as having “severe” ischemia, although quantification of ischemic burden on stress EKG has limited data and poor calibration. This has severely limited the subgroup analysis. Indeed, the results presented showed that patients with severe ischemia had a better prognosis than those with only moderate ischemia (12.7% vs. 13.8% estimated 4-year event rate). While it is tempting to conclude that this trial overturns the vast volume of data showing a strong relationship between ischemia burden and prognosis from many hundreds of thousands of patients across numerous centers, a better interpretation is that the definitions used were flawed and the trial recruitment biased.

The trial was designed as a clinical outcomes study, and not for optimization or comparison of imaging strategies. Furthermore, details of how important ancillary imaging findings such as transient cavity dilation, decrease in ejection fraction, and stress induced symptoms were incorporated into core lab decisions have not been explained. In clinical practice, these factors are often at least as important as perfusion defect size to clinical decision making with regards to referral for angiography and revascularization. This may be reflected in the relatively high percentage of patients without symptoms who were randomized (approximately 35%). Generally, asymptomatic patients are considered rarely appropriate for stress testing by professional society Appropriate Use Criteria.

Another serious issue is that there was no requirement for complete revascularization or even for revascularization of territories corresponding to ischemia. There is evidence that even at quaternary medical centers, revascularization is often performed in non-ischemic territories while ignoring other ischemia causing lesions. Of course, with stress EKG, localization of ischemia can be very challenging. It will be critical to assess the concordance between revascularization and ischemic burden to judge whether the primary hypothesis was indeed implemented in the revascularization arm.

Forward Role for Nuclear Stress Testing

First, the prognostic value of nuclear stress testing is extremely well established and is not challenged by this trial, which was not optimized for this question. Second, nuclear methods continue to advance with marked improvements in accuracy and reductions in radiation dosimetry. Thus far, there has been no data presented with regards to types or capabilities of cameras or to the protocols employed. Unfortunately, an international survey showed many centers are using outdated techniques and protocols with suboptimal performance. Of note, only 10% of the included perfusion studies were
performed in the United States, and thus may not reflect optimized clinical protocols nor those in use today.(12)

Third, availability of cardiac nuclear imaging is broad as is expertise in interpretation of these studies. Finally, nuclear stress testing can be performed effectively in patients with renal or lung disease, irregular cardiac rhythms, and obesity – which represent challenges to alternative testing strategies. Consequently, there will continue to be an important role for nuclear methods in the prognostic assessment of patients with known or suspected CAD and intermediate or higher clinical risk.

One limitation raised has been the rate of left main coronary stenosis in this population (5.8%) on blinded coronary computed tomography angiography performed prior to randomization. This suggests a potential role for coronary computed tomography angiography (CCTA) after stress testing in intermediate to high risk patients with moderate to large perfusion defects but also re-emphasizes the importance of identifying findings on stress testing associated with high or low rates of left main involvement. Several of these have already been identified, but further work would be fruitful.(13–16) One important limitation is that approximately 11% of those randomized could not undergo CCTA due to reduced renal function.

Another major change will likely be a reduction in overall revascularization volumes with a primary focus on optimal medical therapy. Remaining referrals for revascularization of non-left main stenosis will be increasingly focused on revascularization for symptom improvement.(2) Anatomic stenosis and invasive measures of ischemia such as fractional flow reserve (FFR) are unable to identify patients who accrue a symptomatic improvement with revascularization (17), although ischemia burden on stress imaging is able to do so.(18–20) This is an important role for stress imaging for directing revascularization to those most likely to benefit and an advantage compared to anatomic approaches for diagnosis.

Conclusion
Although no doubt numerous secondary analyses will be performed to further characterize the data, this study should drive changes in clinical practice. Appropriate use criteria should be refined to emphasize revascularization for symptomatic benefit of anginal symptoms and quality of life in most patients, although outcomes improvement has not been ruled out for patients with severe degrees of ischemia. It will be important to review appropriate use criteria for stress imaging to re-emphasize focus on patients with intermediate to high risk of CAD complications and to continue to improve quality of implementation of nuclear stress imaging in clinical practice. Nonetheless, stress nuclear myocardial perfusion imaging will continue to have an important clinical role for the foreseeable future.

Disclosures
Dr. Murthy, Dr. Bateman, Dr. Chen, Dr. Malhotra, Dr. Miller, and Dr. Ruddy are currently President, Vice President, Secretary, Treasurer, Vice President-Elect, and Immediate Past President of the Cardiovascular Council of the Society of Nuclear Medicine and Molecular Imaging. Dr. Dilsizian is President of the Society of Nuclear Medicine and Molecular Imaging. Dr. Murthy owns stock in General Electric and Cardinal Health and stock options in Ionetix. He has received consulting fees from Ionetix and Curium and payment for expert witness testimony from Jubilant Draximage. He has received non-financial research support from INVIA Medical Imaging Solutions. He is the principal investigator on grants from the National Heart, Lung, and Blood Institute (R01HL136685) and the National Institute on
Aging (RO1AG05972). Dr. Bateman has received research grants from Bracco, General Electric Healthcare, Jubilant Draximage. Dr. Bateman is a consultant for AIM, AstraZeneca, Curium and General Electric Healthcare. Dr. Bateman receives royalties related to SPECT and PET software and owns stock in CVIT. Dr. Ruddy has received grants from General Electric Healthcare and Advanced Accelerator Applications. Dr. Miller is a consultant for General Electric Healthcare, Pfizer, Eidos and Alnylam. He receives research grants from Eidos, Bracco, Pfizer and Alnylam. Dr. Malhotra is a consultant for Akcea Therapeutics and on the speaker's bureau for Pfizer. Dr. Malhotra receives research support from Canon Medical Systems.

References


